PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för sotagliflozin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

37 hits

Bibliografisk träff 2024-05-01

Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.

Deshmukh NJ, Kalshetti MS, Patil M, Autade P, Sangle GV.

Clin Exp Pharmacol Physiol · journal article · DOI 10.1111/1440-1681.13854

Bibliografisk träff 2024-02-01

Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction.

Kim I, Cho HJ, Lim S, Seok SH, Lee HY.

Exp Mol Med · published erratum; correction · DOI 10.1038/s12276-023-01154-2

Bibliografisk träff 2024-01-01

Inpefa (sotagliflozin).

Pape Z, El-Alfy AT, Busse K.

WMJ · journal article

Bibliografisk träff 2023-12-23

Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials.

Dos Santos Borges R, de Oliveira Almeida G, Alves VFC, Nienkotter TF, Bertoli ED, Simões E Silva AC.

J Nephrol · meta-analysis; systematic review; journal article · DOI 10.1007/s40620-023-01818-2

Bibliografisk träff 2023-11-29

Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.

Bantounou MA, Sardellis P, Thuemmler R, Black Boada D, Kaczmarek J, Mahmood R, Plascevic J, Philip S.

Diabetes Obes Metab · meta-analysis; systematic review; journal article · DOI 10.1111/dom.15364

Bibliografisk träff 2023-11-28

Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.

Long A, Salvo M.

Ann Pharmacother · review; journal article · DOI 10.1177/10600280231211179

Bibliografisk träff 2023-11-17

Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis.

Li J, Zhu C, Liang J, Hu J, Liu H, Wang Z, Guan R, Chow J, Yan S, Li L, Ma F, Ma G.

Front Pharmacol · systematic review; systematic-review; journal article · DOI 10.3389/fphar.2023.1303694

Bibliografisk träff 2023-11-15

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats.

Zhong P, Zhang J, Wei Y, Liu T, Chen M.

Heliyon · research-article; journal article · DOI 10.1016/j.heliyon.2023.e22423

Bibliografisk träff 2023-11-01

Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.

Aggarwal R, Bhatt DL, Szarek M, Cannon CP, McGuire DK, Inzucchi SE, Lopes RD, Davies MJ, Banks P, Pitt B, Steg PG.

J Am Coll Cardiol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jacc.2023.08.050

Bibliografisk träff 2023-11-01

Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level.

Fonarow GC, Mohebi R.

J Am Coll Cardiol · comment; research support, non-u.s. gov't; editorial · DOI 10.1016/j.jacc.2023.09.004

Bibliografisk träff 2023-09-19

Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality.

Iyer N, Hussein S, Singareddy S, Sn VP, Jaramillo AP, Yasir M, Nath TS.

Cureus · review-article; review; journal article · DOI 10.7759/cureus.45525

Bibliografisk träff 2023-08-14

Sotagliflozin for Heart Failure: What We Know About Trials and Mechanisms.

Packer M.

J Card Fail · journal article · DOI 10.1016/j.cardfail.2023.08.003

Bibliografisk träff 2023-08-01

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.

Pitt B, Bhatt DL, Szarek M, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Ezekowitz JA, Sun F, Davies MJ, Verma S, Kosiborod MN, Steg PG, SOLOIST-WHF Investigators.

JACC Heart Fail · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jchf.2023.05.026

Bibliografisk träff 2023-07-31

Sotagliflozin: an insight into the first dual SGLT inhibitor now approved for heart failure.

Affan M, Dar MS.

Ir J Med Sci · letter · DOI 10.1007/s11845-023-03474-8

Bibliografisk träff 2023-07-10

Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease.

Cherney DZI, Bhatt DL, Szarek M, Sun F, Girard M, Davies MJ, Pitt B, Steg PG, SCORED Investigators.

Diabetes Obes Metab · research support, non-u.s. gov't; journal article · DOI 10.1111/dom.15203

Bibliografisk träff 2023-07-02

Letter to the Editor: Latest FDA Approved Drug Sotagliflozin (Inpefa): A Glance at its Prospectives for Heart Failure.

Talha M, Ali MH.

Curr Probl Cardiol · letter · DOI 10.1016/j.cpcardiol.2023.101897

Bibliografisk träff 2023-07-01

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3.

Sridhar VS, Heerspink HJL, Davies MJ, Banks P, Girard M, Garg SK, Cherney DZI.

Diabetes Care · research support, non-u.s. gov't; letter; journal article · DOI 10.2337/dc23-0129

Bibliografisk träff 2023-07-01

Sotagliflozin (Inpefa) for heart failure.

Författaruppgift saknas

Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1681b

Bibliografisk träff 2023-06-15

Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.

Pérez MS, Rodríguez-Capitán J, Requena-Ibáñez JA, Santos-Gallego CG, Urooj Zafar M, Escolar G, Mancini D, Mitter S, Lam D, Contreras JP, Fergus I, Atallah-Lajam F, Abascal V, Lala A, Moreno P, Moss N, Lerakis S, Sanz J, Fuster V, Badimon JJ.

Cardiovasc Drugs Ther · clinical trial protocol; research support, non-u.s. gov't; journal article · DOI 10.1007/s10557-023-07469-6

Bibliografisk träff 2023-06-01

Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.

Becher PM, Savarese G, Benson L, Dahlström U, Karlström P, Mol PGM, Metra M, Bhatt DL, Pitt B, Lund LH.

Eur Heart J Cardiovasc Pharmacother · research support, non-u.s. gov't; journal article · DOI 10.1093/ehjcvp/pvad012

Bibliografisk träff 2023-06-01

Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction.

Kim I, Cho HJ, Lim S, Seok SH, Lee HY.

Exp Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s12276-023-01002-3

Bibliografisk träff 2023-04-01

Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure.

Verma S, Bhatt DL, Dhingra NK, Steg PG, Szarek M, Davies M, Metra M, Lund LH, Pitt B, SOLOIST Investigators.

J Am Coll Cardiol · letter · DOI 10.1016/j.jacc.2023.02.022

Bibliografisk träff 2023-03-20

Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.

Stougaard EB, Rossing P, Vistisen D, Banks P, Girard M, Davies MJ, Persson F.

Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.15047

Bibliografisk träff 2023-02-28

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.

Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Powell DR, Davies MJ, Banks P, Agarwal R.

Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.15019

Bibliografisk träff 2022-11-04

Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials.

Wu J, Zhao X, Chen H, Zhu S.

J Diabetes Complications · meta-analysis; journal article · DOI 10.1016/j.jdiacomp.2022.108352

Bibliografisk träff 2022-10-28

Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction.

Gong Y, Kong B, Shuai W, Chen T, Zhang J, Huang H.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2022.175357

Bibliografisk träff 2021-10-04

Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.

Avgerinos I, Karagiannis T, Kakotrichi P, Michailidis T, Liakos A, Matthews DR, Tsapas A, Bekiari E.

Diabetes Obes Metab · meta-analysis; research support, non-u.s. gov't; systematic review; journal article · DOI 10.1111/dom.14555

Bibliografisk träff 2021-08-20

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.

Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Carroll AK, Lapuerta P, Banks P, Agarwal R.

Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.14513

Bibliografisk träff 2021-06-28

Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF.

Zhao LM, Ding LL, Zhan ZL, Qiu M.

Cardiovasc Drugs Ther · letter; meta-analysis · DOI 10.1007/s10557-021-07203-0

Bibliografisk träff 2021-04-09

Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial.

Shah SR, Ali A, Ikram S.

Expert Rev Clin Pharmacol · editorial · DOI 10.1080/17512433.2021.1908123